Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

https://lnkd.in/eEyn69r

UPDATED 4/2022

We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022

https://pharmaceuticalintelligence.com/2022/04/25/we-celebrate-ten-years-of-excellence-lpbi-group-4-2012-4-2022/

2022 Update from LPBI Group | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

Picture updated on 2/6/2022

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile

Roles on 1.0 LPBI Group’s present mission:

(1) Transfer of IP Ownership, and

(2) Team’s Exit as one human capital unit

Sourcing IB(s) and or Acquirer(s)
Shepard the Exit transaction completion
Transition under the new ownership of LPBI IP portfolio of 10 asset classes and the team of experts

Roles on 2.0 LPBI Group’s New Strategies #1,2,3,4,5,6 for 1/2021 – 12/2025

Author: 2020=2021 VISION

https://pharmaceuticalintelligence.com/vision/

Updated on 2/26/2022

The List of INNOVATIONS since Dr. Lev-Ari transitioned to HEALTHCARE, 2005

Developed in 2006-2007 at neu.edu a combination drug therapy to prevent cardiovascular major event. The original six articles are the first articles published in PharmaceuticalIntelligence.com
4/2012 developed the Methodology of Curations for the clinical interpretation of research findings reported in basic research peer reviewed articles. This methodology was applied as the work plan for the Open Access Scientific Journal launched with the name PharmaceuticalIntelligence.com
Initiated the 1^st Transition of LPBI Group: from Journal publishing to e-Book publishing, known as BioMed e-Series, 5 specialties in Medicine, 18 volumes https://pharmaceuticalintelligence.com/biomed-e-books/
Developed the architecture of electronic Table of Contents (eTOCs) for e-Books. LPBI was the 1^st publisher in the World to build eTOCs from an archive of Journal articles
Developed platforms, portals, composition of methods allowing for the development of several digital products, among them:
E-Proceedings and Tweet Collections – two formats for Press coverage of Conferences in Biotech and Medicine. The digital products include: Curation methodology, Journal Article Style Sheet, eTOCs for Books and several Portals
Brought to LPBI the concept of Medical Text Analysis with Natural Language Processing (NLP) using Wolfram Language for Biological Sciences
Mentored Yash to develop code for Statistical NLP and for Deep Learning (defining 1^st and 2^nd levels)
Requested Yash to start with 25 concept extractions from merged files
Instituted the manual review of this computer output for culling a subset of concepts and remove connective words included in the computer output by running Concept Extraction code
Brought Linguamatics to experiment with our text on their platform – GREAT RESULTS for us: +600 connections of gene-drug, drug-disease, gene-disease
Defined the NLP protocol for Medical Text Analysis on our Books to involve: WordClouds, Bar diagrams, Hypergraph Tree Diagrams and Domain Knowledge Expert Interpretation of the results in an Interpretation Box

https://pharmaceuticalintelligence.com/2021/07/15/workflow-for-a-ten-steps-medical-text-analysis-operation-using-nlp-on-lpbi-medical-and-life-sciences-content/

13. Launched a BLOCKCHAIN IT design for a Transaction enabled IS for LPBI Group and brought BurstIQ over to design the 1st architecture draft of a Blockchain for LPBI Group’s IP. Specified in 2^nd round the need for interface of NLP with the Blockchain

14. Brought Erich over to launch Fluree.com and knowledge graph DATABASE SCHEMA with Madison Davis

15. Brought the Text To Sound (TTS) conversion company in the UK [SpeechKit, now, Beyondwords.com] allowing for the LIBRARY of Podcast to be launched. TTS was applied on the Category of Research: Interviews with Scientific Leaders (N= 287, 180 were converted to Sound in 8/2021)

16. Interviewed three Spanish Translation companies and brought the contract with Montero signed and paid and Translations delivered in 6 months – 18 books (cover page and eTOCs) allowing for the launch of NEW Genre of Scientific Books:

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

17. Launched the Mission #4: Synthetic Biology Software for drug design and brought over from Weizmann Institute Dr. Nir London with PRosettaC for PROTACs

https://pharmaceuticalintelligence.com/2021/10/21/the-map-of-human-proteins-drawn-by-artificial-intelligence-and-protac-proteolysis-targeting-chimeras-technology-for-drug-discovery/

18. Brought over Dr. Raphael Nir, jointly decided to target Galectins. LPBI Group’s Team had expanded to the universe of 12 from his interest in #3

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

19. Introduced the relevance of Scientific NFT for LPBI Group’s Portfolio of IP Assets

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

20. Defined The Gallery of Biological Images as #nft of #priorart

21. Ascertained that LPBI Group’s Scientific NFT for LPBI Group’s Portfolio of IP is included in the launch of 1^st World NFT Marketplace for IP in Science and Technology, March 2022 announcement by Dr. Alex Liu [He may come back to Board Meeting on 3/15/2022].

ACTIVITIES in 1Q 2021

Pulling strings at the highest levels related to Exit – our life in 2.0 LPBI post first IB exploration.
Works with Amanda on Article Views for 2020 data
Continues to perfect the VISION for six strategies and four initiatives

https://pharmaceuticalintelligence.com/vision/

The LIFE of Content Monetization Strategy – Designed the Data Architecture for the Blockchain IT infrastructure

https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/

The LIFE of Medical Text Analysis Project

See all Updates in 1/2021, 12/2020, 11/2020 in 2020-2021 Vision

https://pharmaceuticalintelligence.com/vision/

Wrote Recommendation Letters for Madison and Irina. Forthcoming Recommendation Letters: Danielle, Adina, Amanda
The LIFE of 1.0 LPBI – continue to publish in the Journal and on Coronavirus Portal
Will upload/PUBLISH in 1/2021 VOLUME #18 on Reproductive Genomics and Endocrinology [6+2+2+4+4 = 18]
Interviewing NEW members of the External Business Relations Panel
Running the Calendar & the Agenda for LPBI GLOBAL Monthly Zoom Meeting ~30 attendees – NEXT on 2/9/2021 and BEYOND in 2021
Works with Robin to bring over 18 NEW Interns for IT Initiatives and for Medical Text Analysis on [6+2+2+4+4 = 18] Books.
Preparing for submission ALL eTOCs for 18 Volumes for translation “English to Spanish” for a Pharmaceutical Publisher in Barcelona
Working with Joel on a 10 Page PowerPoint and on Financials for NLP Products
WILL CONDUCT on 3/30/2021 a ONE-on-ONE with All ACTIVE FIT members and with the INTERNS – we will look together on

PERSONAL PORTALS (FIT members) and
PERSONAL PAGES (Interns).

BIO

Professional Preparation

Bouve College of Health Sciences, School of Nursing, Four semesters of Independent Research in Cardiovascular Pharmacotherapy with Prof. Paul Abourjaily

Activities and Societies: ANA, MARN

Hebrew University of Jerusalem

BA, MA

Urban Planning, Economic Geography

GPA 95/100

1970 – 1976

Activities and Societies: Israel Poets Association

HUGGIM – High School, Mount Carmel, Haifa, Israel

Baccalaureate in Economics and Political Sciences, 93/100

1964 – 1968

Appointments

Nominations for Awards & Honors

Nominee for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional lifetime achievements reflect the excellence of a UC Berkeley education. Nominator: Sheila M. Puffer (UC, Berkeley, PhD’84).

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

On 3/31/2018, Dr. Lev-Ari, PhD, RN was nominated for the 2018 Yidan Foundation Prize

https://yidanprize.org/

Per request for supporting material, the following was submitted to the nominator, Prof. Marcus W. Feldman of Stanford University, Department of Biology.

Nomination for 2018 Yidan Prize, recognition in the field of medical education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/

8/17/2018, Dr. Lev-Ari, PhD, RN was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board.

http://www.maacadsci.org

MAS FELLOWS

GOVERNING BOARD

ACTIVITIES

On 12/7/2018, Dr. Lev-Ari was nominated for 2019 Berkeley Alumna of the Year Achievement Award

2019 Awardees

https://awards.berkeley.edu/achievement-awards

Biography

On April 2012 had launched the Open Access Online Scientific Journal PharmaceuticalIntelligence.com – 1,811,456 Views and 5,908 scientific articles on 8/26/2020 since launch. It grew to 1,840,183 views and 5,940 scientific articles on 10/10/2020 ~~20,000 a month.

On December 31, 2020 the Open Access Online Scientific Journal PharmaceuticalIntelligence.com –

1,906,438 Views
7,524 Scientific Comments
5,978 articles
723 Research Categories
482,474 Views on Top Authors: Aviva Lev-Ari, PhD, RN

At 1.0 LPBI Group Aviva Lev-Ari, PhD, RN serves as

Administrator of the platform and its Architect since 4/2012, the venture inception. # Views by eReaders of Administrator’s posts 466,589 on 10/10/2020, nearing 1/2 a Million e-Readers.
Is the Launcher of the Website PharmaceuticalIntelligence.com
Is the IP owner with agreements with each Expert, Author, Writer (EAW)
Is the Editor-in-Chief of the

Journal [com] and of
the BioMed e-Series [https://pharmaceuticalintelligence.com/biomed-e-books/]

Is the Co-Editor of several volumes in each series, except Series C: Cancer
Is the Publisher of +3,400 of the 5,900 articles in the Journal
Is the Developer of the Methodology of Curation for Pharmaceutics and Media top article 17,000 views, Several of Aviva’s articles fetched +10,000 views
Is Developer of the Methodology of electronic Table of Contents (eTOCs) creation and was involved in the population of all eTOCs by Expert Editors that culled articles from the journal’s research categories to create ONE of a kind an eTOCs for each volume [except Series C: Cancer]
Is Developer of the Methodology of Real Time Press Coverage of Top Biotech Conferences using social media and the ONE key stroke method for generation of the conference’s eProceedings.
Is The Producer of 60 of the 70 Conference eProceedings in the venture’s Archive of Press Coverage of Biotech and Medical Conferences

https://pharmaceuticalintelligence.com/press-coverage/part-two-list-of-biotech-conferences-2013-to-present/

Lev-Ari is the creator of THREE intellectual property asset classes in Media & Healthcare (pharmaceutical, medicine, medical devices & diagnostics, bioinformatics). The three archives are ready for Text Analysis & Text Mining by AI, ML and NLP algorithms
The three archives consist of the following IP assets:

LPBI Journal:

https://lnkd.in/eEw5q7N

Open Access Online Scientific Journal PharmaceuticalIntelligence.com

A collection of +5,900 scientific articles +1.8Million eReaders, and

The Journal Ontology of +700 categories of Research

Sixteen volumes of Medical Books in Five specialties:

https://lnkd.in/ekWGNqA

Series A: Cardiovascular – 6 volumes, BUNDLED BY AMAZON.COM INTO A SIX-VOLUME SERIES FOR $515

https://lnkd.in/e6WkMgF

Series B: Genomics – 2 volumes

Series C: Cancer – 2 volumes

Series D: Immune system & Infectious Diseases – 3 volumes

Series E: Precision Medicine – 4 volumes

Biotech Conferences Press Coverage with Social Media:

https://pharmaceuticalintelligence.com/press-coverage/

Lev-Ari is the Producer of Biotech & Medical Conference e-Proceedings:

https://lnkd.in/dc2qGAK

Is the developer of the methodology for Real Time Press coverage with social media

The archive of 70 eProceeding documents was produced at 70 Biotech and Medical Conferences covered in Real Time during attendance. Each Conferences yielded on average 4 – 5 new curations in the Journal

Is the creator of the 30 Collections of Tweets she posted in real time at 60 of the 70 Biotech and Medical Conferences listed in

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

Is the presenter of the Twitter Analytics of LPBI Group’s social media coverage of each conference by @pharma_BI and by @AVIVA1950

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers]

CURRICULUM VITAE

PUBLICATIONS @ PharmaceuticalIntelligence.com

Books

Dr. Lev-Ari’s curations are on Cardiovascular Diseases – Six Volumes

https://lnkd.in/e6WkMgF

Series A: e-Books on Cardiovascular Diseases – Six Volumes

Cardiovascular Diseases, Volume One: Perspectives on Nitric Oxide in Disease Mechanisms. On comsince 6/21/2013 https://lnkd.in/8DANfq
Cardiovascular Diseases, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation. On comsince 11/30/2015 https://lnkd.in/ekbuNZ3
Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics. On comsince 11/29/2015 https://lnkd.in/ecp5mrA
Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases. On comsince 12/26/2015 https://lnkd.in/dwqM3K3
Cardiovascular Diseases, Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases. On comsince 12/23/2018 https://lnkd.in/e3r87cQ
Cardiovascular Diseases, Volume Six: Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment. On comsince 12/24/2018 https://lnkd.in/e_CTb4R